PE20120519A1 - Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida - Google Patents

Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida

Info

Publication number
PE20120519A1
PE20120519A1 PE2011001686A PE2011001686A PE20120519A1 PE 20120519 A1 PE20120519 A1 PE 20120519A1 PE 2011001686 A PE2011001686 A PE 2011001686A PE 2011001686 A PE2011001686 A PE 2011001686A PE 20120519 A1 PE20120519 A1 PE 20120519A1
Authority
PE
Peru
Prior art keywords
compound
dioxo
phenyl
dihydropyrimidin
metansulphonamide
Prior art date
Application number
PE2011001686A
Other languages
English (en)
Inventor
James J Napier
Jean-Christophe Califano
Calvin L Becker
Su Yu
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of PE20120519A1 publication Critical patent/PE20120519A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN PROCESO DE OBTENCION DEL COMPUESTO (E)-N-(4-(3-TERT-BUTIL-5-(2,4-DIOXO-3,4-DIHIDROPIRIMIDIN-1(2H)-IL)-2-METOXIESTIRIL)FENIL)METANSULFONAMIDA DE FORMULA (I) QUE COMPRENDE: A) REDUCIR EL COMPUESTO N-(4-((3-TERT-BUTIL-5-(2,4-DIOXO-3,4-DIHIDROPIRIMIDIN-1(2H)-IL)-2-METOXIFENIL)ETINIL)FENIL)METANSULFONAMIDA DE FORMULA (6) EMPLEANDO UN SILANO TAL COMO TRIETILSILANO, FENILSILANO, HEXAMETILDISILANO, ENTRE OTROS, Y EN PRESENCIA DE UN CATALIZADOR DE PALADIO Y UN SOLVENTE TAL COMO DIMETILFORMAMIDA, DIMETILACETAMIDA, ENTRE OTROS. DONDE EL COMPUESTO (6) SE OBTIENE HACIENDO REACCIONAR EL COMPUESTO 1-(3-TERT-BUTIL-5-ETINIL-4-METOXIFENIL)PIRIMIDIN-2,4(1H,3H)-DIONA CON UNO DE LOS COMPUESTOS SELECCIONADOS DE N-(4-YODOFENIL)METANSULFONAMIDA, N-(4-BROMOFENIL)METANSULFONAMIDA, N-(4-CLOROFENIL)METANSULFONAMIDA, ENTRE OTROS, EN PRESENCIA DE UNA BASE Y UN SOLVENTE. DICHO COMPUESTO DE FORMULA (I) ES UTIL PARA INHIBIR EL VIRUS DE LA HEPATITIS C
PE2011001686A 2009-03-24 2010-03-24 Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida PE20120519A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16270509P 2009-03-24 2009-03-24
US31671310P 2010-03-23 2010-03-23

Publications (1)

Publication Number Publication Date
PE20120519A1 true PE20120519A1 (es) 2012-06-03

Family

ID=42136100

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001686A PE20120519A1 (es) 2009-03-24 2010-03-24 Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida

Country Status (24)

Country Link
EP (1) EP2411372B1 (es)
JP (1) JP5744003B2 (es)
KR (1) KR101665955B1 (es)
CN (1) CN102361858B (es)
AU (1) AU2010229975B2 (es)
BR (1) BRPI1009854A2 (es)
CA (1) CA2753825C (es)
CL (1) CL2011002278A1 (es)
CO (1) CO6450678A2 (es)
CR (1) CR20110524A (es)
DO (1) DOP2011000297A (es)
EC (1) ECSP11011415A (es)
ES (1) ES2488821T3 (es)
GT (1) GT201100241A (es)
HK (1) HK1166798A1 (es)
IL (1) IL214858A (es)
MX (1) MX2011010049A (es)
MY (1) MY169288A (es)
NZ (1) NZ594923A (es)
PE (1) PE20120519A1 (es)
RU (1) RU2524573C2 (es)
SG (1) SG174211A1 (es)
WO (1) WO2010111348A1 (es)
ZA (1) ZA201106511B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
MY167881A (en) 2010-07-16 2018-09-26 Abbvie Bahamas Ltd Process for preparing antiviral compounds
MX338725B (es) 2010-07-16 2016-04-28 Abbvie Bahamas Ltd Ligando de fosfina para reacciones cataliticas.
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
CA2829768A1 (en) * 2011-03-18 2012-09-27 Abbvie Inc. Formulations of phenyl uracil compounds
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1219626B1 (en) * 1999-09-20 2005-06-01 Fuji Photo Film Co., Ltd. Compounds for fluorescence labeling
DK1218401T3 (da) * 1999-09-22 2004-10-04 Aventis Pharma Gmbh 4-Benzylaminoquinolin-konjugat med galdesyre og deres heteroanaloger, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
DE10051981A1 (de) * 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
AU2007266915A1 (en) 2006-05-30 2007-12-06 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis C
EP2548873A1 (en) * 2007-09-17 2013-01-23 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
WO2009039127A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Uracil or thymine derivative for treating hepatitis c
JP2011528686A (ja) * 2008-07-23 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス性化合物

Also Published As

Publication number Publication date
IL214858A0 (en) 2011-11-30
CL2011002278A1 (es) 2012-03-09
CO6450678A2 (es) 2012-05-31
CR20110524A (es) 2012-01-19
JP2012521990A (ja) 2012-09-20
EP2411372A1 (en) 2012-02-01
RU2011142757A (ru) 2013-04-27
CN102361858B (zh) 2014-07-23
EP2411372B1 (en) 2014-07-23
JP5744003B2 (ja) 2015-07-01
NZ594923A (en) 2013-11-29
AU2010229975A1 (en) 2011-09-29
DOP2011000297A (es) 2011-10-15
KR20110137372A (ko) 2011-12-22
CA2753825C (en) 2017-10-17
GT201100241A (es) 2015-08-19
CN102361858A (zh) 2012-02-22
RU2524573C2 (ru) 2014-07-27
KR101665955B1 (ko) 2016-10-13
IL214858A (en) 2015-05-31
MY169288A (en) 2019-03-21
AU2010229975B2 (en) 2015-05-21
BRPI1009854A2 (pt) 2015-08-25
ES2488821T3 (es) 2014-08-29
ECSP11011415A (es) 2011-11-30
WO2010111348A1 (en) 2010-09-30
HK1166798A1 (en) 2012-11-09
ZA201106511B (en) 2012-05-30
MX2011010049A (es) 2011-10-11
CA2753825A1 (en) 2010-09-30
SG174211A1 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20120519A1 (es) Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida
PE20090992A1 (es) Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
CO6241076A2 (es) Compuestos de benzamida y aplicaciones de los mismos
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
NZ596538A (en) Haloalkyl heteroaryl benzamide compounds
PE20120257A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
DK1755606T4 (da) Quinazolinonderivater, der er anvendelige som vanilloid-antagonister
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
AR065649A1 (es) Dionas ciclicas herbicidamente activas, procesos de obtencion y composiciones.
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
PE20140923A1 (es) Preparacion solida que comprende alogliptina y clorhidrato de metformina
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
EA200900676A1 (ru) Ингибиторы вируса гепатита с
PE20141996A1 (es) Compuestos con actividad nematicida
CR20110506A (es) Inhibidores de la replicación del virus de la hepatitis c
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
PE20131086A1 (es) Proceso para preparar compuestos antivirales
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
AR051392A1 (es) Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos
ECSP099565A (es) Compuesto de 2-amino pirimidina

Legal Events

Date Code Title Description
FG Grant, registration